Arbutus Biopharma
Arbutus Biopharma's revenue rose 128.2% to $14 million in fiscal 2025. Its operating margin was −271.0%, up from −1,236.7% a year earlier. Free cash flow was −$40 million. The diluted share count rose 3.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Arbutus Biopharma does
Arbutus Biopharma is a clinical-stage drug developer focused on infectious disease. Clinical-stage means its medicines are still being tested in people and none is approved for sale. Its two main candidates are imdusiran, an injected RNA-based treatment, and AB-101, an oral pill, both aimed at chronic hepatitis B, a long-lasting liver infection.
The company has no product sales and says it has had operating losses in nearly every year since it started. Its income comes from licensing its delivery technology, which wraps genetic material in tiny fat-based particles so it can reach cells in the body. It licenses this technology through Genevant, a company in which it owns about 16%, and it is suing Pfizer and BioNTech over their use of it in COVID-19 vaccines. In March 2026 it settled with Moderna, which agreed to pay $950.0 million up front to Arbutus and Genevant together, with more possible later. Arbutus is entitled to 20% of that up-front payment after litigation costs. It also holds a royalty right tied to Alnylam's drug ONPATTRO.
In 2024 and 2025 Arbutus cut its staff sharply, replaced its board and chief executive, closed its Pennsylvania headquarters and stopped in-house research to focus on the hepatitis B programs.
Its biggest risks, as it describes them
- Losing or failing to win its patent lawsuits against large companies such as Pfizer and BioNTech, which cost a lot to pursue.
- The extra Moderna payment depends on a favorable ruling in a limited appeal, and may never be paid.
- Its hepatitis B candidates are early-stage and may not prove safe or effective or win approval.
- It has no product revenue, has lost money in nearly every year and may need more capital.
- The FDA has placed a clinical hold on its AB-101 application, which may take time to lift.
Income statement
Arbutus Biopharma lost money in fiscal 2025: a net loss of $34 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 191 | 184 | 132 | 123 | 92 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −191 | −184 | −132 | −123 | −92 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −25.7x | −37.9x | −170.2x | −557.1x | −393.4x |
| Current ratio | 14.3x | 4.6x | 5.9x | 8.2x | 15.7x |
| Quick ratio | 14.3x | 4.6x | 5.9x | 8.2x | 15.7x |
Cash flow
Projections
Project Arbutus Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Arbutus Biopharma reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 8 | 2 of 8 | 3 of 8 |
| Rule of 40 | −532.8% | −1,119.8% | −153.2% |
| Altman Z'' | −24.58 | −28.68 | −39.67 |
| Accruals ratio | 7.7% | −3.7% | 5.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 1 of 8 | 2 of 8 | 3 of 8 |
Compare
Put Arbutus Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | |
| Relay Therapeutics | FY25 | 53.4% | −1,971.6% | −1,536.1% | — | — | — | Compare |
| Janux Therapeutics | FY25 | −5.5% | −1,576.7% | −832.8% | — | — | — | Compare |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
| Roivant Sciences | FY25 | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 11 | 6 | 6 | 7 | 11 | 39 | 18 | 6 | 14 |
| Revenue growth | −93.6% | 617.6% | −44.4% | 1.1% | 15.0% | 58.9% | 255.1% | −53.5% | −66.0% | 128.2% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 61 | 63 | 58 | 58 | 49 | 66 | 84 | 74 | 54 | 25 |
| Operating income | −492 | −111 | −90 | −144 | −58 | −74 | −66 | −78 | −76 | −38 |
| Net income | −384 | −84 | −57 | −154 | −64 | −76 | −70 | −73 | −70 | −34 |
| Diluted EPS (US$) | −7.24 | −1.56 | −1.21 | −2.89 | −1.00 | −0.83 | −0.46 | −0.44 | −0.38 | −0.17 |
| Diluted shares (millions) | 53 | 55 | 55 | 57 | 76 | 106 | 151 | 166 | 186 | 192 |
| Cash flow | ||||||||||
| Cash from operations | −58 | −49 | −68 | −71 | −51 | −68 | −35 | −86 | −65 | −40 |
| Capital expenditure | 4 | 7 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Free cash flow | −62 | −56 | −69 | −72 | −52 | −68 | −36 | −87 | −65 | −40 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 39 | 15 | 6 | 7 | 6 | 6 | 7 | 9 | 9 | 7 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 131 | 126 | 125 | 91 | 123 | 191 | 184 | 132 | 123 | 92 |
| Debt incl. finance leases | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Total assets | 276 | 237 | 228 | 106 | 137 | 204 | 195 | 144 | 132 | 95 |
| Total liabilities | 73 | 55 | 28 | 33 | 35 | 35 | 59 | 38 | 34 | 18 |
| Shareholders' equity | 203 | 182 | 200 | 73 | 102 | 169 | 137 | 106 | 97 | 77 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −32,973.8% | −1,036.7% | −1,510.2% | −2,394.0% | −836.1% | −669.1% | −167.8% | −430.5% | −1,236.7% | −271.0% |
| Net margin | −25,765.5% | −788.9% | −959.8% | −2,557.4% | −922.0% | −693.9% | −178.0% | −401.6% | −1,133.0% | −237.9% |
| Free cash flow margin | −4,150.3% | −522.5% | −1,160.7% | −1,191.1% | −747.3% | −622.0% | −91.9% | −479.3% | −1,053.8% | −281.4% |
| Rule of 40 (growth + FCF margin) | −4,243.9% | 95.2% | −1,205.2% | −1,190.0% | −732.3% | −563.0% | 163.2% | −532.8% | −1,119.8% | −153.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −102.3% | −43.8% | −29.8% | −112.6% | −73.0% | −56.2% | −45.4% | −60.0% | −68.8% | −38.5% |
| Return on assets | −77.8% | −32.9% | −24.5% | −92.2% | −52.5% | −44.6% | −34.7% | −42.9% | −50.6% | −29.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |